UCB SA (0NZT.IL)
| Previous close | 137.55 |
| Open | 139.05 |
| Bid | 137.25 x 0 |
| Ask | 140.10 x 0 |
| Day's range | 137.85 - 139.05 |
| 52-week range | 65.40 - 139.90 |
| Volume | |
| Avg. volume | 140,527 |
| Market cap | 28.15B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 81.38 |
| EPS (TTM) | 1.70 |
| Earnings date | 24 July 2024 - 03 Aug 2024 |
| Forward dividend & yield | 1.33 (1.84%) |
| Ex-dividend date | 28 Apr 2023 |
| 1y target est | N/A |
PR NewswireFINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia
UCB, a global biopharmaceutical company, today announced that Epilepsia published findings from a comprehensive scoping review examining the efficacy of FINTEPLA® (fenfluramine) in reducing the frequency of generalized tonic-clonic seizures (GTCS) and tonic-clonic seizures (TCS) among patients with developmental and epileptic encephalopathies (DEEs). This analysis highlighted a significant reduction in both GTCS and TCS across various DEEs adding to the already established data from the FINTEPLA
Simply Wall St.Top Value Stocks That Could Be Bargains In June 2024
As global markets continue to navigate through political uncertainties and mixed economic signals, investors are keenly observing shifting trends across various indices. With the S&P 500 and Nasdaq reaching new highs amid a narrow market advance, discerning investors might find potential opportunities in undervalued stocks that could emerge as bargains.
PR NewswireNew CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels
UCB, a global biopharmaceutical company, will present results from three studies for CIMZIA® (certolizumab pegol), a PEGylated fragment crystalized (Fc)-free tumor necrosis factor inhibitor (TNFi), for women of childbearing age living with chronic immune-mediated diseases and people with rheumatoid arthritis (RA) and high rheumatoid factor (RF) levels.1,2,3 These data will be presented at the European Congress of Rheumatology, EULAR 2024, and provide evidence to inform personalized treatment dec
